The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt ...
BridgeBio Pharma, Inc. has announced the pricing of $500 million in convertible senior notes at a 1.75% interest rate, maturing in 2031, in a private offering aimed at qualified institutional buyers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback